Novartis’ Signifor Seeks Controlled-Data Edge In Cushing Market At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Cushing’s disease treatment Signifor (pasireotide) underwent a randomized Phase III clinical trial, while the earlier approval of competitor Corcept Therapeutics’ Korlym (mifepristone) was based on an open-label study.
You may also be interested in...
PTK/ZK Not Dead Yet; R&D Efforts May Shift To Subgroup, Novartis Says
Novartis/Schering AG may shift development of their investigational colorectal cancer agent PTK/ZK 787 (valatanib) to focus on patients with elevated lactate dehydrogenase (LDH) levels, Novartis Oncology President David Epstein said June 7
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.